Prostate cancer cell exposure to IGF-2 results in a reduced IR-B expression and the relative prevalence of IR-A [35] and IR-A:IR-B ratio is significantly increased in primary human prostate cancers compared to benign tissues [34]. This evidence concerns the gene IGF2 and Familial prostate cancer.